Cardioplegin

pharmacoplegic agent for producing cardiac standstill in open-heart surgery; contains procaine, magnesium L-asparaginate & sorbitol

Also Known As:

Magnesate(2-), bis(L-aspartato(2-)-N,O1)-, (T-4)-, dihydrogen, mixt. with 2-(diethylamino)ethyl 4-aminobenzoate monohydrochloride

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/1980 - "Ischemic arrest (45 minutes), injection cardioplegia (2-3 ml/kg body weight within 1 minute) using Cardioplegin (magnesium-aspartate-procaine-sorbitol) according to Kirsch (90 minutes), and infusion cardioplegia (30 ml/kg body weight within 5 to 7 minutes) employing solution LK 352 (sodium-potassium-magnesium-aspartate-sorbitol) according to Bretschneider (90 minutes) were investigated in dogs in order to evaluate their efficacy of protection during myocardial ischemia and their effects on post-ischemic cardiac function. "
2.	Body Weight (Weight, Body) 10/01/1980 - "Ischemic arrest (45 minutes), injection cardioplegia (2-3 ml/kg body weight within 1 minute) using Cardioplegin (magnesium-aspartate-procaine-sorbitol) according to Kirsch (90 minutes), and infusion cardioplegia (30 ml/kg body weight within 5 to 7 minutes) employing solution LK 352 (sodium-potassium-magnesium-aspartate-sorbitol) according to Bretschneider (90 minutes) were investigated in dogs in order to evaluate their efficacy of protection during myocardial ischemia and their effects on post-ischemic cardiac function. "
3.	Hypothermia 01/01/1979 - "In the second group, total body hypothermia to the level desired was used and in the third group, normothermic cardioplegia was induced (Cardioplegin) in normothermic animals. " 04/01/1978 - "[Myocardial protection utilizing hypothermia and cardioplegin during surgical correction of congenital heart disease (author's transl)]."
4.	Congenital Heart Defects (Congenital Heart Defect) 04/01/1978 - "[Myocardial protection utilizing hypothermia and cardioplegin during surgical correction of congenital heart disease (author's transl)]." 06/01/1975 - "Coronary blood flow, myocardial oxygen consumption, and cardiac hemodynamics was measured before and after cardiopulmonary bypass in two group of patients (7 and 4) with minor congenital heart disease where cardiac arrest was induced by means of "cardioplegin" or "external surface cooling" (Shumway). "
5.	Heart Arrest (Cardiac Arrest) 06/01/1975 - "Coronary blood flow, myocardial oxygen consumption, and cardiac hemodynamics was measured before and after cardiopulmonary bypass in two group of patients (7 and 4) with minor congenital heart disease where cardiac arrest was induced by means of "cardioplegin" or "external surface cooling" (Shumway). " 01/01/1979 - "In experiments with dogs, three different methods of inducing a reversible cardiac arrest were compared: (A) the ischemic arrest for 45 min, (B) the cardiac arrest for 90 min due to injection of Cardioplegin according to KIRSCH, and (C) the cardiac arrest for 90 min due to infusion of solution LK 352 according to BRETSCHNEIDER. "

Related Drugs and Biologics

1.	Solutions
2.	sodium- potassium- magnesium- aspartate- sorbitol
3.	Sorbitol (Yal)
4.	magnesium-aspartate-procaine
5.	Procaine (Novocaine)
6.	Magnesium

Related Therapies and Procedures

1.	Induced Heart Arrest (Cardioplegia)
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)